TY - JOUR
T1 - Theoretical potential for endometrial cancer prevention through primary risk factor modification: Estimates from the EPIC cohort.
AU - Fortner, Renée T.
AU - Hüsing, Anika
AU - Dossus, Laure
AU - Tjønneland, Anne
AU - Overvad, Kim
AU - Dahm, Christina C.
AU - Arveux, Patrick
AU - Fournier, Agnès
AU - Kvaskoff, Marina
AU - Schulze, Matthias B.
AU - Bergmann, Manuela
AU - Trichopoulou, Antonia
AU - Karakatsani, Anna
AU - La Vecchia, Carlo
AU - Masala, Giovanna
AU - Pala, Valeria
AU - Mattiello, Amalia
AU - Tumino, Rosario
AU - Ricceri, Fulvio
AU - van Gils, Carla H.
AU - Monninkhof, Evelyn M.
AU - Bonet, Catalina
AU - Quirós, José Ramón
AU - Sanchez, Maria-Jose
AU - Rodríguez-Palacios, Daniel-Ángel
AU - Gurrea, Aurelio B.
AU - Amiano, Pilar
AU - Allen, Naomi E.
AU - Travis, Ruth C.
AU - Gunter, Marc J.
AU - Viallon, Vivian
AU - Weiderpass, Elisabete
AU - Riboli, Elio
AU - Kaaks, Rudolf
N1 - Place: United States
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Endometrial cancer (EC) incidence rates vary textasciitilde10-fold worldwide, in part due to variation in EC risk factor profiles. Using an EC risk model previously developed in the European EPIC cohort, we evaluated the prevention potential of modified EC risk factor patterns and whether differences in EC incidence between a European population and low-risk countries can be explained by differences in these patterns. Predicted EC incidence rates were estimated over 10 years of follow-up for the cohort before and after modifying risk factor profiles. Risk factors considered were: body mass index (BMI, kg/m(2) ), use of postmenopausal hormone therapy (HT) and oral contraceptives (OC) (potentially modifiable); and, parity, ages at first birth, menarche and menopause (environmentally conditioned, but not readily modifiable). Modeled alterations in BMI (to all ≤23 kg/m(2) ) and HT use (to all non-HT users) profiles resulted in a 30 individually, longer duration of OC use (to all ≥10 years) resulted in a 42.5i.e., those not contributing to prevention potential) resulted in ≤24.6 however, this was driven by relatively long use of OCs (median = 23 years). Our findings support avoidance of overweight BMI and of HT use as prevention strategies for EC in a European population; OC use must be considered in the context of benefits and risks.
AB - Endometrial cancer (EC) incidence rates vary textasciitilde10-fold worldwide, in part due to variation in EC risk factor profiles. Using an EC risk model previously developed in the European EPIC cohort, we evaluated the prevention potential of modified EC risk factor patterns and whether differences in EC incidence between a European population and low-risk countries can be explained by differences in these patterns. Predicted EC incidence rates were estimated over 10 years of follow-up for the cohort before and after modifying risk factor profiles. Risk factors considered were: body mass index (BMI, kg/m(2) ), use of postmenopausal hormone therapy (HT) and oral contraceptives (OC) (potentially modifiable); and, parity, ages at first birth, menarche and menopause (environmentally conditioned, but not readily modifiable). Modeled alterations in BMI (to all ≤23 kg/m(2) ) and HT use (to all non-HT users) profiles resulted in a 30 individually, longer duration of OC use (to all ≥10 years) resulted in a 42.5i.e., those not contributing to prevention potential) resulted in ≤24.6 however, this was driven by relatively long use of OCs (median = 23 years). Our findings support avoidance of overweight BMI and of HT use as prevention strategies for EC in a European population; OC use must be considered in the context of benefits and risks.
M3 - Article
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 5
ER -